JP2023071827A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023071827A5 JP2023071827A5 JP2023030635A JP2023030635A JP2023071827A5 JP 2023071827 A5 JP2023071827 A5 JP 2023071827A5 JP 2023030635 A JP2023030635 A JP 2023030635A JP 2023030635 A JP2023030635 A JP 2023030635A JP 2023071827 A5 JP2023071827 A5 JP 2023071827A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- pharmaceutical composition
- composition according
- disease
- glp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 12
- 102000037865 fusion proteins Human genes 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 2
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000000644 isotonic solution Substances 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- 108091006269 SLC5A2 Proteins 0.000 claims 1
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- 229960001713 canagliflozin Drugs 0.000 claims 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000001434 dietary modification Nutrition 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000698 nateglinide Drugs 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229960003611 pramlintide Drugs 0.000 claims 1
- 108010029667 pramlintide Proteins 0.000 claims 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000006337 proteolytic cleavage Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- -1 sulfonylureas Chemical class 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024159697A JP7789871B2 (ja) | 2017-09-22 | 2024-09-17 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562283P | 2017-09-22 | 2017-09-22 | |
| US62/562,283 | 2017-09-22 | ||
| JP2020516667A JP7239566B2 (ja) | 2017-09-22 | 2018-09-21 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
| PCT/US2018/052110 WO2019060653A1 (en) | 2017-09-22 | 2018-09-21 | GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516667A Division JP7239566B2 (ja) | 2017-09-22 | 2018-09-21 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159697A Division JP7789871B2 (ja) | 2017-09-22 | 2024-09-17 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023071827A JP2023071827A (ja) | 2023-05-23 |
| JP2023071827A5 true JP2023071827A5 (enExample) | 2023-10-11 |
| JP7559112B2 JP7559112B2 (ja) | 2024-10-01 |
Family
ID=63799082
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516667A Active JP7239566B2 (ja) | 2017-09-22 | 2018-09-21 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
| JP2023030635A Active JP7559112B2 (ja) | 2017-09-22 | 2023-03-01 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516667A Active JP7239566B2 (ja) | 2017-09-22 | 2018-09-21 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11045522B2 (enExample) |
| EP (1) | EP3684793A1 (enExample) |
| JP (2) | JP7239566B2 (enExample) |
| KR (1) | KR102696518B1 (enExample) |
| CN (2) | CN111108117B (enExample) |
| AU (2) | AU2018338178B2 (enExample) |
| CA (1) | CA3073964A1 (enExample) |
| EA (1) | EA202090649A1 (enExample) |
| IL (2) | IL273253B2 (enExample) |
| MX (1) | MX2020002977A (enExample) |
| MY (2) | MY200364A (enExample) |
| SG (1) | SG11202001637PA (enExample) |
| WO (1) | WO2019060653A1 (enExample) |
| ZA (1) | ZA202001167B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001637PA (en) * | 2017-09-22 | 2020-03-30 | Regeneron Pharma | Glucagon-like peptide 1 receptor agonists and uses thereof |
| US12122817B2 (en) * | 2020-09-22 | 2024-10-22 | Serpentide Inc. | Long-lasting GLP1 analogue drug for type-2 diabetes |
| WO2022119076A1 (ko) * | 2020-12-03 | 2022-06-09 | 이뮤노포지 주식회사 | Glp-1 수용체 작용제 및 항-오스카 항체를 포함하는 융합 단백질 및 이의 용도 |
| WO2022117044A1 (en) * | 2020-12-03 | 2022-06-09 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof |
| CN112716966B (zh) * | 2021-02-03 | 2022-05-03 | 浙江诺得药业有限公司 | 一种恩格列净药用组合物及其制备方法 |
| CN113461785B (zh) * | 2021-04-13 | 2022-10-14 | 湖南中晟全肽生化有限公司 | Glp-1受体激动剂及其应用 |
| CN119638849A (zh) * | 2021-10-18 | 2025-03-18 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
| CN114788876B (zh) * | 2022-02-24 | 2024-07-05 | 北京医院 | 治疗糖尿病的mRNA药物制剂及其制备方法与应用 |
| EP4520350A1 (en) * | 2022-05-04 | 2025-03-12 | ImmunoForge Co., Ltd. | Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| CN117143242B (zh) * | 2023-10-30 | 2024-03-29 | 南京佰抗生物科技有限公司 | 抗Galectin-3蛋白的单克隆抗体组合物及应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250270274A1 (en) * | 2024-02-26 | 2025-08-28 | Serpentide Inc. | Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE525395T1 (de) | 2003-06-12 | 2011-10-15 | Lilly Co Eli | Fusions proteine von glp-1-analoga |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| AR064623A1 (es) | 2006-12-21 | 2009-04-15 | Centocor Inc | Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos |
| WO2009020802A2 (en) | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
| JP5476304B2 (ja) | 2007-09-05 | 2014-04-23 | ノボ・ノルデイスク・エー／エス | グルカゴン様ペプチド−１誘導体及びそれらの医薬用途 |
| JP2012511586A (ja) | 2008-12-10 | 2012-05-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 医薬組成物 |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| WO2011043530A1 (ko) * | 2009-10-09 | 2011-04-14 | (주)알테오젠 | Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물 |
| JP5774595B2 (ja) | 2009-10-28 | 2015-09-09 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｇｌｐ−１ｒ抗体及びそれらの使用 |
| EP2496249B1 (en) | 2009-11-03 | 2016-03-09 | Amylin Pharmaceuticals, LLC | Glp-1 receptor agonist for use in treating obstructive sleep apnea |
| HK1207097A1 (en) | 2012-09-07 | 2016-01-22 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| JP6445459B2 (ja) | 2013-01-17 | 2018-12-26 | ブイティーブイ・セラピューティクス・エルエルシー | Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用 |
| US20150259416A1 (en) | 2014-03-12 | 2015-09-17 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| CN104098702B (zh) * | 2014-07-23 | 2017-06-16 | 湖北工业大学 | 一种利用mfh融合蛋白制备glp‑1多肽或其类似物方法和应用 |
| CN111388680B (zh) * | 2015-01-28 | 2024-01-05 | 中国科学院天津工业生物技术研究所 | 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物 |
| AU2016218759B2 (en) | 2015-02-11 | 2021-11-25 | Gmax Biopharm Llc. | Stabilized solution preparation of pharmaceutical GLP-1R antibody fusion protein |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| CN109195984A (zh) * | 2016-06-09 | 2019-01-11 | 免疫医疗有限公司 | 蛋白酶抗性的单-脂化肽 |
| SG11202001637PA (en) | 2017-09-22 | 2020-03-30 | Regeneron Pharma | Glucagon-like peptide 1 receptor agonists and uses thereof |
-
2018
- 2018-09-21 SG SG11202001637PA patent/SG11202001637PA/en unknown
- 2018-09-21 AU AU2018338178A patent/AU2018338178B2/en active Active
- 2018-09-21 EA EA202090649A patent/EA202090649A1/ru unknown
- 2018-09-21 MX MX2020002977A patent/MX2020002977A/es unknown
- 2018-09-21 WO PCT/US2018/052110 patent/WO2019060653A1/en not_active Ceased
- 2018-09-21 MY MYPI2020000984A patent/MY200364A/en unknown
- 2018-09-21 EP EP18783613.5A patent/EP3684793A1/en active Pending
- 2018-09-21 MY MYPI2023002759A patent/MY207828A/en unknown
- 2018-09-21 KR KR1020207011414A patent/KR102696518B1/ko active Active
- 2018-09-21 US US16/137,662 patent/US11045522B2/en active Active
- 2018-09-21 CN CN201880061327.6A patent/CN111108117B/zh active Active
- 2018-09-21 IL IL273253A patent/IL273253B2/en unknown
- 2018-09-21 IL IL304574A patent/IL304574B2/en unknown
- 2018-09-21 CN CN202410964216.3A patent/CN118955732A/zh active Pending
- 2018-09-21 JP JP2020516667A patent/JP7239566B2/ja active Active
- 2018-09-21 CA CA3073964A patent/CA3073964A1/en active Pending
-
2020
- 2020-02-25 ZA ZA2020/01167A patent/ZA202001167B/en unknown
-
2021
- 2021-05-27 US US17/332,215 patent/US11779633B2/en active Active
-
2023
- 2023-03-01 JP JP2023030635A patent/JP7559112B2/ja active Active
- 2023-08-29 US US18/457,482 patent/US12090193B2/en active Active
- 2023-09-04 AU AU2023223010A patent/AU2023223010B2/en active Active
-
2024
- 2024-08-14 US US18/804,421 patent/US20250000949A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023071827A5 (enExample) | ||
| Tahrani et al. | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus | |
| IL273253B1 (en) | Glucagon-like peptide 1 receptor agonists and uses thereof | |
| JP7642588B2 (ja) | 療法のためｇｉｐ／ｇｌｐ１コアゴニストを使用する方法 | |
| EP4125896B1 (en) | Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| Levien et al. | New drugs in development for the treatment of diabetes. | |
| JP2010031018A5 (enExample) | ||
| TW201247702A (en) | Use of acylated glucagon analogues | |
| KR20090088854A (ko) | 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도 | |
| CN1462191A (zh) | 用glp－1治疗急性冠脉综合征 | |
| WO2023228023A1 (en) | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| AU2020344895B2 (en) | Treatment of type 2 diabetes mellitus | |
| RU2679602C1 (ru) | Состав для лечения сахарного диабета | |
| WO2024027553A1 (zh) | 一种双功能融合蛋白及其用途 | |
| Morales et al. | The use of SGLT2 inhibitors and GLP-1 receptor agonists, a worthwhile physiologic combination in managing type 2 diabetes while reducing cardiovascular risk | |
| Kaur et al. | Hormones and Hormones Antagonists | |
| Górecka et al. | Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome | |
| JP7789871B2 (ja) | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 | |
| WO2025213190A1 (en) | Methods of treating a disease or condition associated with weight gain | |
| Islam | A review on synthesis, characterization, and pharmacological evaluation of second-line antidiabetic drugs | |
| RU2022104898A (ru) | Слитый белок fgf21 fc, слитый белок glp-1 fc и комбинированный терапевтический агент, включающий их, и их применение | |
| CN117915914A (zh) | 治疗肝病的组合疗法 | |
| JPH0680584A (ja) | グリセンチンを有効成分とする医薬 | |
| JP2012526080A (ja) | 抗ＩＬ１−β抗体の併用療法 | |
| NZ772008A (en) | Gip/glp1 co-agonist compounds |